当前位置: 首页 >> 检索结果
1121. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
作者: Qiaoyan Liu.;Bo Li.;Yikang Li.;Yiran Wei.;Bingyuan Huang.;Jubo Liang.;Zhengrui You.;You Li.;Qiwei Qian.;Rui Wang.;Jun Zhang.;Ruiling Chen.;Zhuwan Lyu.;Yong Chen.;Mingxia Shi.;Xiao Xiao.;Qixia Wang.;Qi Miao.;Jing-Yuan Fang.;Merrill Eric Gershwin.;Min Lian.;Xiong Ma.;Ruqi Tang.
来源: Gut. 2022年71卷5期899-909页
Multiple clinical similarities exist between IgG4-related sclerosing cholangitis (IgG4-SC) and primary sclerosing cholangitis (PSC), and while gut dysbiosis has been extensively studied in PSC, the role of the gut microbiota in IgG4-SC remains unknown. Herein, we aimed to evaluate alterations of the gut microbiome and metabolome in IgG4-SC and PSC.
1123. RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
作者: Jiazeng Sun.;Guanhui Wu.;Florentin Pastor.;Naimur Rahman.;Wen-Hung Wang.;Zhengtao Zhang.;Philippe Merle.;Lijian Hui.;Anna Salvetti.;David Durantel.;Danzhou Yang.;Ourania Andrisani.
来源: Gut. 2022年71卷5期991-1005页
RNA helicase DDX5 is downregulated during HBV replication and poor prognosis HBV-related hepatocellular carcinoma (HCC). The objective of this study is to investigate the role of DDX5 in interferon (IFN) signalling. We provide evidence of a novel mechanism involving DDX5 that enables translation of transcription factor STAT1 mediating the IFN response.
1125. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
作者: Jumin Huang.;Di Liu.;Yuwei Wang.;Liang Liu.;Jian Li.;Jing Yuan.;Zhihong Jiang.;Zebo Jiang.;Wl Wendy Hsiao.;Haizhou Liu.;Imran Khan.;Ying Xie.;Jianlin Wu.;Yajia Xie.;Yizhong Zhang.;Yu Fu.;Junyi Liao.;Wenjun Wang.;Huanling Lai.;Axi Shi.;Jun Cai.;Lianxiang Luo.;Runze Li.;Xiaojun Yao.;Xingxing Fan.;Qibiao Wu.;Zhongqiu Liu.;Peiyu Yan.;Jingguang Lu.;Mingrong Yang.;Lin Wang.;Yabing Cao.;Hong Wei.;Elaine Lai-Han Leung.
来源: Gut. 2022年71卷4期734-745页
Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a crucial role in immunotherapy sensitisation and Panax ginseng has been shown to possess immunomodulatory potential. In this study, we aimed to investigate whether the combination treatment of ginseng polysaccharides (GPs) and αPD-1 monoclonal antibody (mAb) could sensitise the response by modulating gut microbiota.
1127. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
作者: Ferenc Emil Mózes.;Jenny A Lee.;Emmanuel Anandraj Selvaraj.;Arjun Narayan Ajmer Jayaswal.;Michael Trauner.;Jerome Boursier.;Céline Fournier.;Katharina Staufer.;Rudolf E Stauber.;Elisabetta Bugianesi.;Ramy Younes.;Silvia Gaia.;Monica Lupșor-Platon.;Salvatore Petta.;Toshihide Shima.;Takeshi Okanoue.;Sanjiv Mahadeva.;Wah-Kheong Chan.;Peter J Eddowes.;Gideon M Hirschfield.;Philip Noel Newsome.;Vincent Wai-Sun Wong.;Victor de Ledinghen.;Jiangao Fan.;Feng Shen.;Jeremy F Cobbold.;Yoshio Sumida.;Akira Okajima.;Jörn M Schattenberg.;Christian Labenz.;Won Kim.;Myoung Seok Lee.;Johannes Wiegand.;Thomas Karlas.;Yusuf Yılmaz.;Guruprasad Padur Aithal.;Naaventhan Palaniyappan.;Christophe Cassinotto.;Sandeep Aggarwal.;Harshit Garg.;Geraldine J Ooi.;Atsushi Nakajima.;Masato Yoneda.;Marianne Ziol.;Nathalie Barget.;Andreas Geier.;Theresa Tuthill.;M Julia Brosnan.;Quentin Mark Anstee.;Stefan Neubauer.;Stephen A Harrison.;Patrick M Bossuyt.;Michael Pavlides.; .
来源: Gut. 2022年71卷5期1006-1019页
Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.
1128. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
作者: Kit Curtius.;Misha Kabir.;Ibrahim Al Bakir.;Chang Ho Ryan Choi.;Juanda L Hartono.;Michael Johnson.;James E East.; .;James O Lindsay.;Roser Vega.;Siwan Thomas-Gibson.;Janindra Warusavitarne.;Ana Wilson.;Trevor A Graham.;Ailsa Hart.
来源: Gut. 2022年71卷4期705-715页
Patients with ulcerative colitis (UC) diagnosed with low-grade dysplasia (LGD) have increased risk of developing advanced neoplasia (AN: high-grade dysplasia or colorectal cancer). We aimed to develop and validate a predictor of AN risk in patients with UC with LGD and create a visual web tool to effectively communicate the risk.
1130. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
作者: Raghav Sundar.;Nesaretnam Barr Kumarakulasinghe.;Yiong Huak Chan.;Kazuhiro Yoshida.;Takaki Yoshikawa.;Yohei Miyagi.;Yasushi Rino.;Munetaka Masuda.;Jia Guan.;Junichi Sakamoto.;Shiro Tanaka.;Angie Lay-Keng Tan.;Michal Marek Hoppe.;Anand D Jeyasekharan.;Cedric Chuan Young Ng.;Mark De Simone.;Heike I Grabsch.;Jeeyun Lee.;Takashi Oshima.;Akira Tsuburaya.;Patrick Tan.
来源: Gut. 2022年71卷4期676-685页
To date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2 factorial randomised phase III study in which patients with GC were randomised to Pac-S-1 (paclitaxel +S-1), Pac-UFT (paclitaxel +UFT), S-1 alone or UFT alone after curative surgery.
1132. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health.
作者: François Brial.;Julien Chilloux.;Trine Nielsen.;Sara Vieira-Silva.;Gwen Falony.;Petros Andrikopoulos.;Michael Olanipekun.;Lesley Hoyles.;Fatima Djouadi.;Ana L Neves.;Andrea Rodriguez-Martinez.;Ghiwa Ishac Mouawad.;Nicolas Pons.;Sofia Forslund.;Emmanuelle Le-Chatelier.;Aurélie Le Lay.;Jeremy Nicholson.;Torben Hansen.;Tuulia Hyötyläinen.;Karine Clément.;Matej Oresic.;Peer Bork.;Stanislav Dusko Ehrlich.;Jeroen Raes.;Oluf Borbye Pedersen.;Dominique Gauguier.;Marc-Emmanuel Dumas.
来源: Gut. 2021年70卷11期2105-2114页
Gut microbial products are involved in regulation of host metabolism. In human and experimental studies, we explored the potential role of hippurate, a hepatic phase 2 conjugation product of microbial benzoate, as a marker and mediator of metabolic health.
1134. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
作者: Seung In Seo.;Chan Hyuk Park.;Seng Chan You.;Jae Young Kim.;Kyung Joo Lee.;Jinseob Kim.;Yerim Kim.;Jong Jin Yoo.;Won-Woo Seo.;Hyung Seok Lee.;Woon Geon Shin.
来源: Gut. 2021年70卷11期2066-2075页
The association between proton pump inhibitor (PPI) use and gastric cancer related to Helicobacter pylori eradication has not been fully investigated in geographical regions with high risk of gastric cancer. We aimed to evaluate the association between PPIs and gastric cancer in Korea.
1135. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
作者: Jonathan W J Lee.;Feng Zhu.;Supriya Srivastava.;Stephen Kk Tsao.;Christopher Khor.;Khek Yu Ho.;Kwong Ming Fock.;Wee Chian Lim.;Tiing Leong Ang.;Wan Cheng Chow.;Jimmy Bok Yan So.;Calvin J Koh.;Shijia Joy Chua.;Andrew S Y Wong.;Jaideepraj Rao.;Lee Guan Lim.;Khoon Lin Ling.;Chung-King Chia.;Choon Jin Ooi.;Andrea Rajnakova.;Wai Ming Yap.;Manuel Salto-Tellez.;Bow Ho.;Richie Soong.;Kee Seng Chia.;Yik Ying Teo.;Ming Teh.;Khay-Guan Yeoh.
来源: Gut. 2022年71卷5期854-863页
To investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC.
1136. Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
作者: Nicolas Hohmann.;Fabian Schröder.;Bernardo Moreira.;Haidong Teng.;Jürgen Burhenne.;Thomas Bruckner.;Sebastian Mueller.;Walter E Haefeli.;Helmut K Seitz.
来源: Gut. 2022年71卷4期842-844页 1138. Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum.
作者: Takashi Nagaishi.;Taro Watabe.;Kunihiko Kotake.;Toshihiko Kumazawa.;Tomomi Aida.;Kohichi Tanaka.;Ryuichi Ono.;Fumitoshi Ishino.;Takako Usami.;Takamasa Miura.;Satomi Hirakata.;Hiroko Kawasaki.;Naoya Tsugawa.;Daiki Yamada.;Kazuhiro Hirayama.;Soichiro Yoshikawa.;Hajime Karasuyama.;Ryuichi Okamoto.;Mamoru Watanabe.;Richard S Blumberg.;Takahiro Adachi.
来源: Gut. 2022年71卷3期487-496页
Although immunoglobulin A (IgA) is abundantly expressed in the gut and known to be an important component of mucosal barriers against luminal pathogens, its precise function remains unclear. Therefore, we tried to elucidate the effect of IgA on gut homeostasis maintenance and its mechanism.
|